Down-regulation of phosphoglucose isomerase/autocrine motility factor enhances gensenoside Rh2 pharmacological action on leukemia KG1α cells

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1099-1104

  You, Zhi Mei ^a   Zhao, Liang ^a   Xia, Jing ^a   Wei, Qiang ^a   Liu, Yu Min ^a   Liu, Xiao Yan ^a   Chen, Di Long ^a   Li, Jing ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Autocrine motility factor; Ginsenoside Rh2; KG1 mTOR; Phosphoglucose isomerase

Indexed keywords

AKT1S1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; GLUCOSE 6 PHOSPHATE ISOMERASE; HOMEODOMAIN PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MTOR PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT EXTRACT; PROTEIN KINASE B; RAG 1 PROTEIN; RAG-1 PROTEIN; RPTOR PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; STRESS ACTIVATED PROTEIN KINASE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; HL 60 CELL LINE; HUMAN; LEUKEMIA; METABOLISM; PANAX; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GLUCOSE-6-PHOSPHATE ISOMERASE; HL-60 CELLS; HOMEODOMAIN PROTEINS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PANAX; PLANT EXTRACTS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84896827391     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1099     Document Type: Article

References (38)

1. Cao MJ, Osatomi K, Matsuda R, et al (2000). Purification of a novel serine proteinase inhibitor from the skeletal muscle of white croaker (Argyrosomus argentatus). Biochem Biophys Res Commun, 272, 485-89.
2. Cheng CC, Yang SM, Huang CY, et al (2005). Molecular mechanisms of ginsenoside Rh2-mediated G1 growth arrest and apoptosis in human lung adenocarcinoma A549 cells. Cancer Chemother Pharmacol, 55, 531-40.
3. Christensen, LP (2009). Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutrition Res, 55, 1-99.
4. Chung KS, Cho SH, Shin JS, et al (2013). Ginsenoside Rh2 induces cell cycle arrest and differentiation in human leukemia cells by upregulating TGF-beta expression. Carcinogenesis, 34, 331-40.
5. Dennis PB, Jaeschke A, Saitoh M, et al (2001). Mammalian TOR: a homeostatic ATP sensor. Science, 294, 1102-5.
6. Fu M, Li L, Albrecht T, et al (2011). Autocrine motility factor/phosphoglucose isomerase regulates ER stress and cell death through control of ER calcium release. Cell Death Differ, 18, 1057-70.
7. Funasaka T, Hogan V, Raz A (2009). Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res, 69, 5349-56.
8. Funasaka T, Hu H, Hogan V, et al (2007). Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence. Journal Chem, 282, 36362-9.
9. Funasaka T, Hu H, Yanagawa T, et al (2007). Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells. Cancer Res, 67, 4236-43.
10. Gingras AC, Raught B, Sonenberg N (2001). Regulation of translation initiation by FRAP/mTOR. Genes Dev, 15, 807-26.
11. Guarino M (2007). Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell bio, 39, 2153-60.
12. Gwinn DM, Shackelford DB, Egan DF, et al (2008). AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell, 30, 214-26.
13. Haga A, Funasaka T, Niinaka Y, et al (2003). Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. International journal of cancer. Int J Cancer, 107, 707-14.
14. Helms S (2004). Cancer prevention and therapeutics: Panax ginseng. Alter Med Rev, 9, 259-74.
15. Huang S, Houghton PJ (2003). Targeting mTOR signaling for cancer therapy. Cur Opin Pharmacol, 3, 371-7.
16. Kho DH, Nangia-Makker P, Balan V, et al (2013). Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells. Cancer Res, 73, 1411-9.
17. Kovacina KS, Park GY, Bae SS, et al (2003). Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem, 278, 10189-94.
18. Lee JM, Dedhar S, Kalluri R, et al (2006). The epithelialmesenchymal transition: new insights in signaling, development, and disease. J Cell Biol, 172, 973-81.
19. Li B, Zhao J, Wang CZ, et al (2011). Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer lett, 301, 185-92.
20. Matsumoto I, Staub A, Benoist C, et al (1999). Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science, 286, 1732-5.
21. Nicholson KM, Anderson NG (2002). The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal, 14, 381-95.
22. Niinaka Y, Harada K, Fujimuro M, et al (2010). Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res, 70, 9483-93.
23. Park EK, Lee EJ, Lee SH, et al (2010). Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt. Br J Pharmacol, 160, 1212-23.
24. Park HM, Kim SJ, Kim JS, et al (2012). Reactive oxygen species mediated ginsenoside Rg3-and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways. Food Chem Toxicol, 50, 2736-41.
25. Sancak Y, Thoreen CC, Peterson TR, et al, (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell, 25, 903-15.
26. Shih WL, Yu FL, Chang CD, et al (2012). Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model. Mol Carcinog, 52, 800-12
27. Tang XP, Tang GD, Fang CY, et al (2013). Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells. World J Gastroenterol, 19, 1582-92.
28. Thiery JP, Sleeman JP (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol, 7, 131-42.
29. Tsutsumi S, Hogan V, Nabi IR, et al (2003). Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res, 63, 242-9.
30. Tsutsumi S, Yanagawa T, Shimura T, et al (2003). Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J Biol Chem, 278, 32165-72.
31. Vander Haar E, Lee SI, Bandhakavi S, et al (2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol, 9, 316-23.
32. Wang W, Wang H, Rayburn ER, et al (2008). 20 (S)-25-methoxyldammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer, 98, 792-802.
33. Wang Z, Zheng Q, Liu K, et al (2006). Ginsenoside Rh (2) enhances antitumour activity and decreases genotoxic effect of cyclophosphamide. Basic Clin Pharmacol Toxicol, 98, 411-5.
34. Wullschleger S, Loewith R, Hall MN (2006). TOR signaling in growth and metabolism. Cell, 124, 471-84.
35. Xu W, Seiter K, Feldman E, et al (1996). The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase. Blood, 87, 4502-6.
36. Yakirevich E, Naot Y (2000). Cloning of a glucose phosphate isomerase/neuroleukin-like sperm antigen involved in sperm agglutination. Biol Reprod, 62, 1016-23.
37. Yanagawa T, Funasaka T, Tsutsumi S, et al (2004). Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. Endocr Relat Cancer, 11, 749-59.
38. Zhang C, Yu H, Hou J (2011). Effects of 20 (S)-ginsenoside Rh2 and 20 (R)-ginsenoside Rh2 on proliferation and apoptosis of human lung adenocarcinoma A549 cells. Zhongguo Zhong Yao Za Zhi, 36, 1670-4.